{
    "clinical_study": {
        "@rank": "8191", 
        "arm_group": [
            {
                "arm_group_label": "Group A (genotypes 1b,4)", 
                "arm_group_type": "Experimental", 
                "description": "Weeks 1-12 = IDX719 50 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily\nWeeks 1-12 = IDX719 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily\nWeeks 1-12 = IDX719 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily"
            }, 
            {
                "arm_group_label": "Group B (genotypes 1b,4 or 6)", 
                "arm_group_type": "Experimental", 
                "description": "Weeks 1-12 = IDX719 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily\nWeeks 1-12 = IDX719 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily\nWeeks 1-12 = IDX719 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily"
            }, 
            {
                "arm_group_label": "Group C (genotypes 1a, 1b)", 
                "arm_group_type": "Experimental", 
                "description": "Weeks 1-12 = IDX719 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily\nWeeks 1-12 = IDX719 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Parts A and B of this study are designed to evaluate the safety, tolerability, efficacy and\n      pharmacokinetic profiles of IDX719 and simeprevir when administered in combination with\n      ribavirin (RBV) for 12 weeks in treatment-na\u00efve, Genotype 1b, 4 and 6 HCV-infected subjects.\n\n      Part C of this study is designed to evaluate the safety, tolerability, efficacy and\n      pharmacokinetic profiles of IDX719, simeprevir, TMC647055 and ritonavir (RTV) when\n      administered in combinations with or without RBV for 12 weeks in treatment-na\u00efve or\n      interferon/RBV-treatment relapsed, Genotype 1a and 1b HCV-infected subjects."
        }, 
        "brief_title": "IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have Genotype 1a, 1b, 4 or 6 HCV infection.\n\n          -  Documented clinical history compatible with chronic hepatitis C\n\n          -  HCV treatment-na\u00efve or interferon/RBV-treatment relapsed (Part C)\n\n          -  Must agree to use an acceptable double method of birth control (one of which must be\n             a barrier method) for at least 6 months after the last dose of study drugs.\n\n        Exclusion Criteria:\n\n          -  Female subjects who are pregnant or breastfeeding.\n\n          -  Body Mass Index (BMI) > 36 kg/m2.\n\n          -  Co-infected with hepatitis B virus or human immunodeficiency virus (HIV).\n\n          -  History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.\n\n          -  History or signs of decompensated liver disease:  ascites, variceal bleeding, hepatic\n             encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal\n             hypertension or hepatic insufficiency.\n\n          -  Has one or more known primary or secondary causes of liver disease, other than\n             hepatitis C\n\n          -  History of, or active, acute or chronic, liver or biliary injury due to drugs,\n             toxins, non-HCV viral hepatitis, gallstones or other etiologies\n\n          -  Donated blood or had significant blood loss 30 days prior to dosing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "143", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852604", 
            "org_study_id": "IDX-06A-005"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A (genotypes 1b,4)", 
                    "Group B (genotypes 1b,4 or 6)", 
                    "Group C (genotypes 1a, 1b)"
                ], 
                "description": "IDX719 will be supplied as 25 mg and 50 mg tablets.", 
                "intervention_name": "IDX719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A (genotypes 1b,4)", 
                    "Group B (genotypes 1b,4 or 6)", 
                    "Group C (genotypes 1a, 1b)"
                ], 
                "description": "Simeprevir will be supplied as 75 and 150 mg capsules.", 
                "intervention_name": "simeprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A (genotypes 1b,4)", 
                    "Group B (genotypes 1b,4 or 6)", 
                    "Group C (genotypes 1a, 1b)"
                ], 
                "description": "Ribavirin will be supplied as 200 mg tablets.", 
                "intervention_name": "ribavirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group C (genotypes 1a, 1b)", 
                "description": "TMC647055 will be supplied as 150 mg capsules.", 
                "intervention_name": "TMC647055", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group C (genotypes 1a, 1b)", 
                "description": "Ritonavir will be supplied as 80 mg/mL oral solution.", 
                "intervention_name": "ritonavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Ritonavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HCV", 
            "Hepatitis C", 
            "chronic hepatitis C", 
            "antiviral"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of subjects having adverse events (AEs).", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of subjects with undetectable plasma HCV RNA at the following timepoints:\nSustained virologic response (SVR4): 4 weeks after the end of treatment\nRapid virologic response (RVR): Week 4 during treatment\nEarly virologic response (EVR): Week 12 at the end of treatment\nSVR8: 8 weeks after the end of treatment\nSVR12: 12 weeks after the end of treatment\nSVR24: 24 weeks after the end of treatment", 
                "measure": "Antiviral Activity", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 weeks"
            }, 
            {
                "description": "Plasma drug exposure of IDX719, simeprevir, TMC647055 and RTV AUC0-t, Cmax and Ctrough", 
                "measure": "Pharmacokinetic Parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "source": "Idenix Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Idenix Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}